bluebird bio

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Bluebird bio reports strong financials and plans for expansion

Bluebird bio demonstrated financial strength and successful gene therapy launches.
Challenges include potential submission delay and operational complexities.
Opportunities lie in expanding patient demand, optimizing strategies, and exploring international markets.
Overall, Bluebird bio remains confident in its products and market positioning.

Bluebird bio excels in gene therapy market, faces manufacturing challenges

Bluebird bio is making significant strides in gene therapy, with successful commercial launches and a strong financial position.
Challenges lie in adapting to a different manufacturing process for lovo-cel and ensuring operational efficiency for future launches.
Opportunities abound in expanding commercial reach, leveraging expertise for targeted launches, and strategic decision-making on PRV monetization.

Bluebird bio reports revenue growth and milestones in Q3

Bluebird bio's Q3 performance showed revenue growth and positive momentum in key product launches.
The company faces challenges related to safety concerns, manufacturing issues, and analyst inquiries.
Strengths lie in a well-established commercial infrastructure and strategic pricing approach.
Opportunities include financing plans, potential voucher sale, and expansion of treatment centers.

bluebird bio reports revenue growth and eyes U.S. expansion opportunities

bluebird bio's Q4 performance showed revenue growth and extended cash runway
Strengths lie in commercial progress, multibillion-dollar U.S. opportunity, and margin improvement
Challenges include financial restatement, reimbursement dynamics, and Medicaid coverage
Opportunities exist in ex U.S. markets, expansion plans, and optimizing reimbursement strategies

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

Bluebird Bio Inc (NASDAQ: BLUE) completed the rolling submission of its marketing application to the FDA seeking approval for betibeglogene autotemcel (beti-cel) gene therapy. The application covers adult, adolescent, and pediatric patients with β-thalassemia who require regular red blood cell (RBC) transfusions across all genotypes.

Bluebird Bio Files US Application For β-thalassemia Gene Therapy

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE--bluebird bio, Inc. (Nasdaq: BLUE) today announced it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for betibeglogene autotemcel (beti-cel) gene therapy in adult, adolescent and pediatric patients with β-thalassemia who require regular red blood cell (RBC) transfusions, across all genotypes. The FDA previously granted beti-cel Orphan Drug status and Breakthrough Therapy designation

bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With β-thalassemia Who Require Regular Red Blood Cell Transfusions

Beam Therapeutics

Cellectis SA

CRISPR Therapeutics

Editas Medicine

Intellia Therapeutics

Regeneron Pharmaceuticals

Gene editing stocks will take off as the underlying tech moves from fiction to fact and companies put their products on the market. The post 7 Gene Editing Stocks Promising to Change our DNA appeared first on InvestorPlace.

7 Gene Editing Stocks Promising to Change our DNA

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, the planned oncology spin-off of bluebird bio (NASDAQ: BLUE) announced today that it will host a series of investor events to share further detail on its research pipeline and strategy. Session One: An Introduction to 2seventy's Pipeline; focus on AML [DARIC33] and Next-Gen Multiple Myeloma Strategy September 21, 2021, 11:00am-12:00pm ET Session Two: Focus on bNHL [bbT369] and Solid Tumor Strategy September 22, 2021, 1:00-2:00pm ET To access the

2seventy bio Announces Upcoming Investor Events

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock?

Why Is Bluebird (BLUE) Down 13.3% Since Last Earnings Report?

Amarin Corporation Plc

Arcturus Therapeutics

Arena Pharmaceuticals

Cassava Sciences Inc

Theravance Biopharma

Buying biotech stocks while they're down is rewarding once they post positive clinical results, setting the stage for a big rally. The post 7 Busted Biotech Stocks Due for a Rebound appeared first on InvestorPlace.

7 Busted Biotech Stocks Due for a Rebound

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) announced today that it has entered into an agreement for a $75 million private placement of common stock and common stock equivalents with a healthcare investment fund selected as part of a competitive process. Proceeds from the financing will support ongoing R&D and commercialization investments for bluebird bio and for 2seventy bio, which plan to launch as independent companies in October 2021. The closing of the privat

bluebird bio Secures $75 Million in Private Placement Equity Financing

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced key management and board appointments in advance of the company's planned separation, targeted for mid-October, 2021. The company also outlined plans for investor events and participation in investor conferences leading up to the separation. “As we approach separation, we are focused on ensuring that both bluebird bio and 2seventy bio have strong management teams and boards in place to carry each company throug

bluebird bio Announces Key Management and Board Appointments and Upcoming Investor Events

Lucira Health

Vertex Pharmaceuticals

These biotech stocks might be down, but they're not out.

3 Beaten-Down Biotech Stocks to Buy Right Now

BLUE is trading near its cash/cash equivalent per share, pointing that the ticker is oversold.

bluebird bio - The Good, The Bad And The Ugly

bluebird continues to struggle with their gene therapy programs. The company announced that the FDA placed another clinical hold on one of their gene therapy programs. The company recently reported their Q2 earnings which revealed a big miss on EPS and revenue. In addition, the company is closing up shop in Europe.

bluebird bio: Throwing My Thesis In The Can And Starting Over From Scratch

bluebird (BLUE) reports a wider-than-expected loss in second-quarter 2021 and also misses revenue estimates. Shares down in pre-market trading as FDA places clinical hold eli-cel.

bluebird (BLUE) Q2 Loss Wider Than Expected, Revenues Fall Y/Y

After the FDA placed a clinical hold on Bluebird Bio Inc's (NASDAQ:BLUE) cerebral adrenoleukodystrophy gene therapy, SVB Leerink downgraded the stock to Market Perform from Outperform. Analyst Mani Foroohar also slashed the price target to $20, down from $64.

SVB Leerink Says 'We Were Wrong,' Slashes Bluebird Bio Price Target

The drugmaker had a double whammy of bad news.

Why Bluebird Bio Stock Is Crashing Today

Bluebird Bio, Inc. (BLUE) CEO Nick Leschly on Q2 2021 Results - Earnings Call Transcript

Shares of bluebird bio (NASDAQ:BLUE) moved higher by 0.9% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 852.78% year over year to ($3.43), which missed the estimate of ($3.19).

Recap: bluebird bio Q2 Earnings

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the second quarter ended June 30, 2021 and provided operational updates, including the announcement that the U.S. Food and Drug Administration (FDA) placed a clinical hold on clinical studies of elivaldogene autotemcel (eli-cel, Lenti-D™) gene therapy (licensed as SKYSONA™ in Europe) for cerebral adrenoleukodystrophy (CALD). “I'm tremendously proud of what bluebird h

bluebird bio Reports Second Quarter Financial Results and Provides Operational Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that the Company will report financial results for the second quarter ended June 30, 2021 on Monday, August 9, 2021 and host a conference call to discuss the quarterly update on Monday, August 9, 2021 at 8 a.m. ET. Investors may listen to the call by dialing (844) 825-4408 from locations in the United States or +1 (315) 625-3227 from outside the United States. Please refer to conference ID number 9698691. Addit

bluebird bio Announces Q2 Earnings Call and Upcoming Investor Events

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 85,000 shares of common stock and 50,000 restricted stock units (“RSUs”) to a newly hired employee with a grant date of August 2, 2021 (the “Inducement Grants”). The Inducement Grants are subject to the terms and conditions of award agreements covering the grants and the Company

bluebird bio, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

After receiving yet another treatment approval from regulators, Bluebird Bio looks like a bargain.

Is This Small-Cap Biotech a Buy After Its Second Approved Gene Therapy?

Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Bluebird Bio (BLUE) to Report a Decline in Earnings: What to Look Out for

SAN DIEGO & BOSTON & CAMBRIDGE, Mass.--(BUSINESS WIRE)--National Resilience, Inc. (Resilience) and bluebird bio, Inc. (NASDAQ: BLUE), today announced a strategic alliance aimed to accelerate the early research, development and delivery of cell therapies. As part of the agreement, Resilience will acquire bluebird's Research Triangle (bRT) manufacturing facility located in North Carolina and retain all of the more than 100 highly skilled technical staff and administrators currently employed at th

Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the European Commission (EC) has granted marketing authorization of SKYSONA™ (elivaldogene autotemcel, Lenti-D™), a one-time gene therapy for the treatment of early cerebral adrenoleukodystrophy (CALD) in patients less than 18 years of age with an ABCD1 genetic mutation, and for whom a human leukocyte antigen (HLA)-matched sibling hematopoietic (blood) stem cell (HSC) donor is not available. SKYSONA is the

bluebird bio Receives EC Approval for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age With Early Cerebral Adrenoleukodystrophy (CALD) Without Matched Sibling Donor

Merck

Organon & Co

Neither healthcare stock has performed well so far this year.

Should Investors Hold Out Hope for bluebird bio and Merck Spinoff Organon?

European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has concluded that the benefit-risk of Bluebird Bio Inc's (NASDAQ: BLUE) Zynteglo (betibeglogene autotemcel gene therapy) remains favorable. Hence EMA is lifting the voluntary marketing suspension on Zynteglo indicated for patients with transfusion-dependent β-thalassemia.

News for bluebird bio Stock (BLUE)